Literature DB >> 26573521

Laboratory assessments in the course of Parkinson's disease: a clinician's perspective.

Thomas Müller1, Horst Baas2, Jan Kassubek3, Peter Riederer4, Peter Paul Urban5, Christoph Schrader6, Heinz Reichmann7, Dirk Woitalla8, Manfred Gerlach9.   

Abstract

Physicians, caregivers and patients themselves must be alert to the onset of and changes in motor and non-motor features during the course of Parkinson's disease (PD). Parallel laboratory routine assessments are necessary because of the evolving impairment of the general health status of the individual. A number of potential biomarkers for the diagnosis of PD are currently under investigation, with diagnosis early in the disease course a particular goal, even before the onset of motor symptoms. The aim of this guideline article is to provide user-friendly, clinical evidence-based recommendations for using laboratory pathological testing for the diagnosis and differential diagnosis of PD, for assessing its time course, and managing complications of long-term dopaminergic therapy and the disabling motor features that develop in the later stages of the disease.

Entities:  

Keywords:  Diagnosis; Laboratory; Levodopa; Parkinson’s disease; Surveillance

Mesh:

Substances:

Year:  2015        PMID: 26573521     DOI: 10.1007/s00702-015-1481-6

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  25 in total

1.  Striatal dopaminergic metabolism is increased by deep brain stimulation of the subthalamic nucleus in 6-hydroxydopamine lesioned rats.

Authors:  W Meissner; T Reum; G Paul; D Harnack; R Sohr; R Morgenstern; A Kupsch
Journal:  Neurosci Lett       Date:  2001-05-11       Impact factor: 3.046

2.  Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy.

Authors:  Davide Manca; Giovanni Cossu; Daniela Murgia; Andrea Molari; Paola Ferrigno; Emanuele Marcia; Maurizio Melis
Journal:  Mov Disord       Date:  2009-11-15       Impact factor: 10.338

3.  Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism.

Authors:  E Martignoni; M Cosentino; M Ferrari; G Porta; E Mattarucchi; F Marino; S Lecchini; G Nappi
Journal:  Neurology       Date:  2005-12-13       Impact factor: 9.910

4.  Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease.

Authors:  Ivana Devic; Hyejin Hwang; John Scott Edgar; Kenneth Izutsu; Richard Presland; Catherine Pan; David R Goodlett; Yu Wang; Jeff Armaly; Vitor Tumas; Cyrus P Zabetian; James B Leverenz; Min Shi; Jing Zhang
Journal:  Brain       Date:  2011-02-24       Impact factor: 13.501

Review 5.  Psychiatric issues in cognitive impairment.

Authors:  Dag Aarsland; John-Paul Taylor; Daniel Weintraub
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

6.  Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients.

Authors:  Thomas Müller; Christoph Erdmann; Dirk Bremen; Wolfgang E Schmidt; Siegfried Muhlack; Dirk Woitalla; Oliver Goetze
Journal:  Clin Neuropharmacol       Date:  2006 Mar-Apr       Impact factor: 1.592

7.  Deep brain stimulation induces striatal dopamine release in obsessive-compulsive disorder.

Authors:  Martijn Figee; Pelle de Koning; Sanne Klaassen; Nienke Vulink; Mariska Mantione; Pepijn van den Munckhof; Richard Schuurman; Guido van Wingen; Thérèse van Amelsvoort; Jan Booij; Damiaan Denys
Journal:  Biol Psychiatry       Date:  2013-08-12       Impact factor: 13.382

8.  The PRIPS study: screening battery for subjects at risk for Parkinson's disease.

Authors:  D Berg; J Godau; K Seppi; S Behnke; I Liepelt-Scarfone; S Lerche; H Stockner; A Gaenslen; P Mahlknecht; H Huber; K Srulijes; J Klenk; K Fassbender; W Maetzler; W Poewe
Journal:  Eur J Neurol       Date:  2012-08-01       Impact factor: 6.089

Review 9.  Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics.

Authors:  Manfred Gerlach; Walter Maetzler; Karl Broich; Harald Hampel; Lucas Rems; Torsten Reum; Peter Riederer; Albrecht Stöffler; Johannes Streffer; Daniela Berg
Journal:  J Neural Transm (Vienna)       Date:  2011-07-14       Impact factor: 3.575

10.  Saliva α-Synuclein and A High Extinction Coefficient Protein: A Novel Approach in Assessment Biomarkers of Parkinson's Disease.

Authors:  Marwan S M Al-Nimer; Sabah F Mshatat; Hajer I Abdulla
Journal:  N Am J Med Sci       Date:  2014-12
View more
  2 in total

Review 1.  Management of Psychosis in Parkinson's Disease: Emphasizing Clinical Subtypes and Pathophysiological Mechanisms of the Condition.

Authors:  Raquel N Taddei; Seyda Cankaya; Sandeep Dhaliwal; K Ray Chaudhuri
Journal:  Parkinsons Dis       Date:  2017-09-12

2.  Antidepressant-Like Properties of Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinson's Disease.

Authors:  Veronica Antipova; Carsten Holzmann; Alexander Hawlitschka; Martin Witt; Andreas Wree
Journal:  Toxins (Basel)       Date:  2021-07-20       Impact factor: 4.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.